Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$71.36M$71.36Mderived+427.6% vs Q4 2023 Net Income-$10.79M-$10.79MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$7,632,000N/M Operating Cash Flowderived-$748,000N/M Free Cash Flowderived-$748,000N/M Margins · derivedOperating margin-10.7%+441.5 pt vs Q4 2023
Net margin-15.1%+474.9 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 25, 2025 · 56 d after period end